Indian Journal of Gynecologic Oncology - The objectives were to study the pattern of expression of PD-L1 in patients with carcinoma cervix and find out any relation with the various patient- and...Lathika, Aryakrishna S.Gynec Oncology Clinic, Regional Cancer Centre, Thiruvananthapuram, India...
cancers Louisa Mezache1, Bernard Paniccia1, Angelique Nyinawabera1 and Gerard J Nuovo1,2 1Phylogeny Inc., Powell, OH, USA and 2OSU Comprehensive Cancer Center, Columbus, OH, USA Programmed death ligand 1 (PD L1) expression can reduce the immune response in both infectious diseases and ...
Anti-PD-1Objectives: To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients with recurrent or metastatic cervical cancer. To determine the association between histology and programmed ...
• Investigator-assessed PFS per RECIST 1.1 in patients whose tumors express PD-L1. 依据RECIST1.1,研究者评估的PD-L1阳性患者的PFS Secondary endpoints/次要研究终点 • PFS in the in the ITT population (i.e. with any PD-L1 expression level i...
Hsp90 expression was up-regulated in HPV16+ cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2...
PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. Background Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall surv...
Samples in the EMT cluster exhibited high 'reactive' pathway scores11 (Supplementary Fig. 20), illustrating for the first time in cervical cancer the presence of a subset of stromal reactive tumours that have high expression of caveolin-1, MYH11 and RAB11, a subset which also appears in ...
“Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer...
PD-L1 IHC 22C3 pharmDx for Cervical CancerPD-L1 IHC 22C3 pharmDx for Cervical Cancer 中国总部 | 其他分公司 北京市朝阳区望京北路 3 号 100102 全球电子邮件 +86 800-820-3278 +86 400-820-3278 全球联系电话 关于安捷伦 新闻中心 公司信息 投资商关系 工作 社会关系 与安捷伦合作 大学关系 环境...
Thus, Hsp90 upregulated PD-L1 signaling that further enhances the immunosuppressive microenvironment in tumors, which prompted the investigation of cervical cancer therapies targeting Hsp90 [17]. Schwock et al. discovered that Hsp90 inhibitor geldanamycin derivative 17-DMAG induced apoptosis in cervical...